Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: March 2023
-
By Kevin E. Noonan – During oral argument before the Supreme Court on Monday in Amgen v. Sanofi, all three advocates (Jeff Lamken for Amgen, Paul Clement for Sanofi, and Colleen Sindzak for the United States) had reason to reference and discuss an amicus brief submitted on behalf of Nobel Prize-winning scientist Sir Gregory Winter and…
-
By Kevin E. Noonan – The Supreme Court's decision to grant certiorari in Amgen v. Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. § 112(a). While these circumstances themselves might motivate amici to file briefs with…
-
By Kevin E. Noonan – The Supreme Court's decision to grant certiorari in Amgen v. Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. § 112(a). While these circumstances themselves might motivate amici to file briefs with…
-
By Kevin E. Noonan – The Supreme Court's decision to grant certiorari in Amgen v. Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. § 112(a). While these circumstances themselves might motivate amici to file briefs with…
-
By Kevin E. Noonan – The Supreme Court's decision to grant certiorari in Amgen v. Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. § 112(a). While these circumstances themselves might motivate amici to file briefs with…
-
J A Kemp will be offering a webinar entitled "Priority Entitlement in Europe — Current Best Practice" on March 21, 2023 at 16:00 pm (GMT). Andrew Clark and Guy Brain of J A Kemp will review European case law and practice in this area and outline practical steps and measures that can be taken by…
-
Strafford will be offering a webinar entitled "Obtaining and Managing REMS Patents: What Patent Prosecutors Need to Know, USPTO and FDA Policies and Rules" on March 21, 2023 from 1:00 to 2:30 pm (EDT). Joanna T. Broughet of BioPharma Law Group and Mark J. Feldstein, Thomas L. Irving, and Adriana L. Burgy of Finnegan Henderson…
-
By Kevin E. Noonan – The Supreme Court's decision to grant certiorari in Amgen v. Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. § 112(a). While these circumstances themselves might motivate amici to file briefs with…
-
By Kevin E. Noonan – Amgen recently filed its Reply brief to the Supreme Court in Amgen v. Sanofi. While a conventional proportion of Amgen's Reply is directed to arguments Respondent Sanofi made in its brief, at trial, and before the Federal Circuit, significant portions of the Reply brief are focused on the Federal Circuit's grounds…
-
March 14, 2023 – "Prep, Prosecution & Profitability: Thoughtful Strategies for Managing to The Bottom Line" (IPWatchdog and UnitedLex) – 11:00 am (ET) March 15, 2023 – "Best Practices for Searching IP5 Literature" (Patent Information Users Group, Inc.) – 10:00 am to 11:00 am (EDT) March 15, 2023 – "The Unified Patent Court Is Coming…
Patent Docs 